Chemical Company of Malaysia Berhad Annual Report 2019

Dividends (continued) The Directors propose a final ordinary dividend of 2.00 sen per ordinary share totalling RM3,353,920 in respect of the financial year ended 31 December 2019 for shareholders’ approval at the forthcoming Annual General Meeting. The financial statements for the current financial year do not reflect this proposed final dividend. Such dividend, if approved by the shareholders, will be accounted for in equity as an appropriation of retained earnings during the financial year ending 31 December 2020. Directors of the Company The names of the Directors of the Company in office since the beginning of the financial year to the date of this report are: Dato’ Idris bin Kechot (Appointed on 18 March 2019) Nik Fazila binti Nik Mohamed Shihabuddin, Group Managing Director Dato’ Wan Mohd Fadzmi bin Che Wan Othman Fadzilah Amizar binti Mizuar Datuk Anuar bin Ahmad (Appointed on 14 June 2019) Raja Azura binti Raja Mahayuddin (Appointed on 21 June 2019) Hasman Yusri bin Yusoff (Appointed on 13 September 2019) Dr. Leong Yuen Yoong (Appointed on 18 September 2019) Zainal Abidin bin Jamal (Appointed on 20 September 2019) Dr. Leong Chik Weng (Retired on 28 May 2019) Datin Paduka Kartini binti Hj Abdul Manaf (Retired on 28 May 2019) Dato’ Azmi bin Mohd. Ali (Resigned on 8 October 2019) Khalid bin Sufat (Resigned on 11 October 2019) Dato’ Seri Ir. Dr. Zaini bin Ujang (Resigned on 1 January 2020) The names of the Directors of the subsidiaries are set out in the respective subsidiaries’ financial statements, where applicable, and the said information is deemed incorporated herein by such reference and made a part hereof. Directors’ interests in shares None of the Directors holding office at 31 December 2019 had any interest in the ordinary shares and options of the Company and of its related companies during the financial year. Directors’ benefits Since the end of the previous financial year, no Director of the Company has received nor become entitled to receive any benefit (other than those fees and other benefits included in the aggregate amount of remuneration received or due and receivable by Directors as shown in the financial statements and Related Party Transactions (Note 28) or the fixed salary of a full time employee of the Company or of related corporations) by reason of a contract made by the Company or a related corporation with the Director or with a firm of which the Director is a member, or with a company in which the Director has a substantial financial interest. There were no arrangements during and at the end of the financial year which had the object of enabling Directors of the Company to acquire benefits by means of the acquisition of shares in or debentures of the Company or any other body corporate. BUSINESS OVERVIEW OTHER INFORMATION GOVERNANCE STRUCTURE 113 ANNUAL REPORT 2019 FINANCIAL STATEMENTS